stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Operating cash flow
Exelixis, Inc.'s operating cash flow for fiscal 2025 was $884.3M, up 26.3% from $700.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.2B. Over the past ten years it has ranged from −$141.1M (fiscal 2015) to $884.3M (fiscal 2025) — the current reading is the highest in ten years. Exelixis, Inc. ranks 7th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $884.3M | 26.33% |
| FY2024 | $700.0M | 110.00% |
| FY2023 | $333.3M | (8.08%) |
| FY2022 | $362.6M | (9.53%) |
| FY2021 | $400.8M | 91.79% |
| FY2020 | $209.0M | (60.34%) |
| FY2019 | $527.0M | 26.76% |
| FY2018 | $415.7M | 151.02% |
| FY2017 | $165.6M | (21.29%) |
| FY2016 | $210.4M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $280.0M | (9.03%) |
| Jun 2026 | $307.7M | 22.19% |
| Mar 2026 | $251.8M | (24.49%) |
| Dec 2025 | $333.5M | 14.88% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.7B |
| EXEL Exelixis, Inc. | $1.2B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $955.9M |
| HALO Halozyme Therapeutics, Inc. compare | $898.3M |
| ASND Ascendis Pharma A/S compare | $404.1M |
| BNTX BioNTech SE Sponsored ADR compare | −$277.2M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.0M |
| SMMT Summit Therapeutics PLC compare | −$458.4M |
| INSM Insmed, Inc. compare | −$595.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement